Department of Pathology

Debra L. Zynger, MS, MD

Professor

Debra L. Zynger, MD

Phone:

614-293-7705

E-mail:

Email Dr. Zynger

Office Location:

E401 Doan Hall

Mailing Address:

E401 Doan Hall
410 W 10th Ave
Columbus, OH 43210

Biosketch

Debra L. Zynger, MS, MD, is a Professor in the Department of Pathology and Department of Urology. She is the Director of the Division of Urologic Pathology.

Dr. Zynger earned an MS in Genetics from Stanford University and MD from Indiana University. She completed her residency training in Anatomic and Clinical Pathology at Northwestern University and Urologic Pathology Fellowship at the University of Pittsburgh.

Dr. Zynger has coauthored 2 Urologic Pathology textbooks, published over 100 journal articles, served as a peer reviewer for 44 journals and is on 5 editorial boards. Dr. Zynger is the Editor in Chief for PathologyOutlines, Ohio Delegate Chair for the College of American Pathologists, serves on the Board of Governors for The Ohio Society of Pathologists and presents numerous talks at national conferences.

Dr. Zynger’s research interests are:

  1. Usage, accuracy, cost and value within urologic pathology specimens
  2. Improving consistency in synoptic reporting of urologic cancer
  3. Bladder cancer prognostication and pathologic reporting
  4. Identification of novel urologic diagnostic biomarkers
  5. Quality improvement in breast cancer pathology

Medical students are very involved in conducting research with Dr. Zynger. During her time at The Ohio State University, 35 medical students, 12 resident and fellow trainees and 2 undergraduate students have achieved authorship on a journal publication with Dr. Zynger as the senior investigator. Their work has been recognized with 42 research awards.

Board Certifications

Anatomic Pathology, American Board of Pathology

Academic and Medical Appointments

Professor, Clinical Scholars Track, Departments of Pathology and Urology, The Ohio State University, Columbus OH

Director, Division of Urologic Pathology

Divisions of Urologic Pathology and Breast Pathology

Additional Resources

Amazon Listings ResearchGate

Education and Training

2009 Fellow, Urologic Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA

2008 Resident, Anatomic and Clinical Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL

2004 M.D., Indiana University School of Medicine, Indianapolis, IN

1999 M.S., Genetics, Stanford University, Stanford, CA

Selected Publications

Search in PubMed

  • D Wu, CT Lee, DL Zynger. Reclassifying pT3 renal pelvic urothelial carcinoma with renal parenchyma invasion to pT2 improves correlation with overall survival. Human Pathology. 2022 Jul;125:79-86. PMID: 35307402.
  • AT Taylor, S Dason, DL Zynger. Clinicopathologic Features of Scrotal Leiomyosarcoma. Human Pathology. 2022 Jun;124:96-102. PMID: 35378116.
  • SJ Wegman, JG Tretter, DL Zynger. Implementation of a Required Third Year Medical Student Surgical Pathology Clinical Experience. Academic Pathology. 2022 Mar 25;9(1):100027. PMID: 35573389.
  • M Siedow, M Eisner, I Washington, A Yaney, DL Zynger, D Martin, X Mo, D DiCostanzo, D Diaz Pardo. Impact of Prostate Biopsy Secondary Pathology Review on Radiotherapy Management. Prostate. 2022 Feb;82(2):210-215. PMID: 34698410.
  • MDC Rodriguez Pena, SC Portillo, A Ali, M Aron, P Colombo, R Cox, D Ertoy, I Gallegos, F Khani, M Květoslava, R Lucianò, H Miyamoto, AO Osunkoya, MR Raspollini, DF Sanchez, F Scarfo, J So, DL Zynger, S Wei, GJ Netto, C Magi-Galluzzi. Testicular Germ Cell Tumors with Spermatic Cord Involvement: A Retrospective International Multi-Institutional Experience. Modern Pathology. 2022 Feb;35(2):249-255. PMID: 34504308.
  • M Akgul, 50 co-authors including D Zynger, M Idrees. Diagnostic Approach in TFE3-Rearranged Associated Renal Cell Carcinoma: A Multi-Institutional International Survey. Journal of Clinical Pathology. 2021 May;74(5):291-299. PMID: 33514585.
  • SW Fine, K Trpkov, MB Amin, F Algaba, M Aron, DE Baydar, A Lopez Beltran, F Brimo, JC Cheville, M Colecchia, E Comperat, I Werneck da Cunha, W Delprado, AM DeMarzo, GA Giannico, JB Gordetsky, CC Guo, DE Hansel, MS Hirsch, J Huang, PA Humphrey, RE Jimenez, F Khani, Q Kong, ON Kryvenko, LP Kunju, P Lal, M Latour, T Lotan, F Maclean, C Magi-Galluzzi, R Mehra, S Menon, H Miyamoto, R Montironi, GJ Netto, JK Nguyen, AO Osunkoya, A Parwani, BD Robinson, MA Rubin, RB Shah, JS So, H Takahashi, Fabio Tavora, MS Tretiakova, L True, SE Wobker, XJ Yang, M Zhou, DL Zynger, JI Epstein. Practice Patterns Related to Prostate Cancer Grading: Results of a 2019 Genitourinary Pathology Society (GUPS) Clinician Survey. Urologic Oncology. 2021 May;39(5):295.e1-295.e8. PMID: 32948433.
  • JI Epstein, MB Amin, SW Fine, F Algaba, M Aron, DE Baydar, A Lopez Beltran, F Brimo, JC Cheville, M Colecchia, E Comperat, I Werneck da Cunha, W Delprado, AM DeMarzo, GA Giannico, JB Gordetsky, CC Guo, DE Hansel, MS Hirsch, J Huang, PA Humphrey, RE Jimenez, F Khani, Q Kong, ON Kryvenko, LP Kunju, P Lal, M Latour, T Lotan, F Maclean, C Magi-Galluzzi, R Mehra, S Menon, H Miyamoto, R Montironi, GJ Netto, JK Nguyen, AO Osunkoya, A Parwani, BD Robinson, MA Rubin, RB Shah, JS So, H Takahashi, Fabio Tavora, MS Tretiakova, L True, SE Wobker, XJ Yang, M Zhou, DL Zynger, K Trpkov. The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Archives of Pathology and Laboratory Medicine. 2021 Apr 1;145(4):461-493. PMID: 32589068.
  • T Sheetz, J Mills, A Tessari, M Pawlikowski, AE Braddom, T Posid, DL Zynger, C James, V Embrione, K Parbhoo, C Foray, V Coppola, CM Croce, D Palmieri. NCL inhibition exerts antineoplastic effects against prostate cancer cells by modulating oncogenic microRNAs. Cancers. 2020 Jul 10;12(7):E1861. PMID: 32664322.
  • Z Xian, JO Orien, GN Box, DL Zynger. Does Intratumoral Adipose or Osseous Metaplasia Confound the Diagnosis of Renal Cell Carcinoma? Diagnostic Pathology. 2020 Mar 6;15(1):21. PMID: 32143646.
  • HT Nguyen, ZK Shah, A Mortazavi, KS Pohar, L Wei, DL Zynger, MV Knopp. Periodically rotated overlapping parallel lines with enhanced reconstruction acquisition to improve motion-induced artifacts in bladder cancer imaging: Initial findings. Medicine. 2019 Oct;98(42):e17075. PMID: 31626080.
  • EL Johnson, DL Zynger. Utility of AMACR in the Diagnosis of Urothelial Carcinoma in Situ: Expression in Difficult Cases. Diagnostic Pathology. 2019 Aug 16;14(1):91. PMID: 31419984.
  • CM Perrino, JA Orien, JG Tretter, W Zhao, DL Zynger. Clinical Utility of Fluorescence In Situ Hybridization (FISH) for Deletion of Chromosome 3p in the Work-Up of Renal Masses. Applied Immunohistochemistry and Molecular Morphology. 2019 Aug;27(7):549-557. PMID: 29912766.
  • EL Johnson, DL Zynger. Utility of AMACR in the Diagnosis of Urothelial Carcinoma in Situ: Expression in Difficult Cases. Diagnostic Pathology. 2019 Aug 16;14(1):91. PMID: 31419984.
  • G Tozbikian, M George, DL Zynger. Diagnostic Terminology Used to Describe Atypia on Breast Core Needle Biopsy: Correlation with Excision and Upgrade Rates. Diagnostic Pathology. 2019 Jun 29;14(1):69. PMID: 31253155.
  • Zynger DL, Pernick N. Understanding the Pathology Job Market: An Analysis of 2330 Pathology Job Advertisements From 2013 Through 2017. Archives of Pathology and Laboratory Medicine.2019 Jan;143(1):9-10. PMID: 30785304.
  • Wegman SJ, Parwani AV, Zynger DL. CK7, inhibin, and p63 in testicular germ cell tumor: superior markers of Choriocarcinoma compared to β-hCG. Human Pathology. 2018 Oct 22. Epub ahead of print. PMID: 30359635.
  • Tozbikian GH, Zynger DL. A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple negative breast Cancer. Human Pathology. 2018 Nov 20. Epub ahead of print. PMID: 30468800.
  • S Prathibha, KG Goyal, DL Zynger. Initial Diagnosis of Insignificant Cancer, HGPIN, ASAP and Negative Have the Same Rate of Upgrade to Gleason ≥7 on Repeat Prostate Biopsy. Human Pathology. 2018 Sept;79:116–121. PMID: 29803813.